Yposkesi Launches AAVelocity ‘Plug-and-Play’ AAV Platform

This new platform has the potential to offer more flexibility in producing viral vectors for clinical and commercial use. The AAVelocity plug-and-play platform can provide a 12-month turnaround on drug developer projects, reducing industry average standard bioprocessing timeframes by at least six months and helping clients save on associated costs.

In addition, AAVelocity provides flexibility by enabling bioproduction teams to easily adapt to clients’ requirements. Features such as achieving different purity levels within strict time constraints, delivering AAVs containing optimized amounts of genetic material, and avoiding intermediary steps or the addition of others, ensure total integrity and purity of the genetic material.

AAVelocity key features:

• High yields: 3×1010 VG/mL up to 2×1011 VG/mL
• Scalable from 250ml for R&D, up to 1,000L for cGMP batches
• Robustness: No loss of titer when scaling-up
• Enriched: >80% full particles

The improved efficacy of AAVelocity will bring greater benefits to drug developers and their pipelines, according to SK pharmteco. Using single-use bioreactors, the AAV platform is scalable to meet any client need: 10L > 50L > 200L > 2 x 200L > 1000L.

How are you enjoying this news article? Let us know your thoughts, here >>

“Leveraging Yposkesi’s many years of expertise, SK pharmteco is able to offer a genuine cost and time-effective solution for AAV manufacturing to stay in step with the increasing development and approvals of C&GT treatments we are witnessing today, which are set to evolve in the near future,” said Alain Lamproye, Yposkesi division head.

The strengthening of AAV manufacturing at its subsidiary aligns with SK pharmteco’s positioning to meet the growing demand. Lamproye adds:

“AAVelocity will bring tangible benefits to the C&GT market: high yields, scalability, robustness, consistency and flexibility like no other. Clients can also benefit considerably from Yposkesi’s strong track record in AAV manufacturing and its experience of participating in filing six IND1/IMPD of AAV-based products since 2017.”

According to the Nice Insight report ‘Cell and Gene Therapy: 2023 Market Analysis, CDMO Pricing and Benchmarking’: “AAV-based therapies are set for greater approval number and approval of treatments for more prevalent diseases,” making it the most represented viral vector within those therapies starting in 2025. By 2028: “Sales of AAV-associated cell and gene therapies are projected to be 72% higher than LV-based therapies.”

Further capabilities, including plasmid manufacturing, process development, GMP vector manufacturing suites, integrated testing & analytics, regulatory services and an adherent AAV manufacturing platform, are available at the Center for Breakthrough Medicines (CBM), SK pharmteco’s US clinical and commercial viral vector manufacturing subsidiary for C&GT.

Source: Yposkesi Press Release, received via email

While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.